Last updated 5 months ago

Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention

72 patients around the world
Available in Brazil
Stanford University
72Patients around the world

Requirements for the patient

From 18 Years
All Gender

Medical requirements

Eligible for latent tuberculosis treatment by Brazil's national guidelines*
provides written informed consent to participate in the study
Evidence of active tuberculosis or currently under evaluation for active tuberculosis
Receiving drugs that interact with Rifapentine (e.g. methadone, warfarin)
Known intolerance or hypersensitivity to isoniazid or rifapentine
Prior treatment for active or latent tuberculosis > 14 days
Close contact to isoniazid- or rifampicin-resistant tuberculosis (TB) case
Neutropenia (absolute neutrophil count <1000 cells/mm3)
Clinical diagnosis of active liver disease or alcohol dependence
alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy